RNS Number:2789Q
Medical Marketing Int'l Group PLC
29 September 2003


FOR IMMEDIATE RELEASE                                 29 SEPTEMBER 2003




                    MEDICAL MARKETING INTERNATIONAL GROUP PLC
                                        
                                        
                   BIOSCIENCE VCT : INTERIM RESULTS COMMENTARY


Medical Marketing International Group plc ("MMI") (LSE:MMG) the Cambridge,
UK-based technology management company listed on the London Stock Exchange has
today commented on Friday's interim results for the Bioscience VCT (LSE:BVP) to
which MMI is the Technology Advisor.


The full interim statement from BioScience VCT can be viewed via the RNS web
site (www.londonstockexchange.com).


David Best, Chairman of MMI, commenting on these results said: "The decision by
the BioScience VCT to retain most of its funds on deposit whilst the valuation
of biotechnology stocks was in decline has meant that the fund has preserved its
cash. Interest accrued has been paid back to shareholders by way of a dividend.
Sensing a change in investor sentiment, the BioScience VCT was able to make
successful investments in Genzyme Transgenic Corporation and Cobra
Biomanufacturing during the period. It is pleasing to note that the fund has
achieved gains of 220% and 40% respectively in each of these investments. The
whole BioScience team are now actively reviewing a significant number of
opportunities and further investments are likely to be made in the near future."


MMI generates fees for being Technology Advisor to BioScience VCT and
additionally, through 'TekCheck', MMI's technical and commercial due diligence
service, where it has 'preferred provider' status.


For further information, please contact:

David Best - Executive Chairman
MMI Group                                              Tel: +44 (0)1223 477677
www.mmigroup.co.uk
--------------------

Lisa Baderoon
Buchanan Communications                               Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCMGGZLMLRGFZM